15 Years of IGB: Developing new drugs to battle cancer
In honor of the IGB's anniversary, we're revisiting some of the history of our institute over the past 15 years with a series of articles highlighting IGB people, projects, and research.
In honor of the IGB's anniversary, we're revisiting some of the history of our institute over the past 15 years with a series of articles highlighting IGB people, projects, and research.
Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.